GlassScriptPhysician profile
Madhurika Samakur
NPI 1306042791
$23,077.24
in general payments reported to CMS, 2019-2025
37 companies · $3,566 in 2025
The $3,566 reported for 2025 was more than what 81% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,101 · 2020: $3,728 · 2021: $2,271 · 2022: $3,482 · 2023: $3,306 · 2024: $3,624 · 2025: $3,566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $99.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,396.20 |
| Education | $99.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,265.07 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $2,465.24 | 2019-2025 | Enbrel, Tavneos, Krystexxa |
| Horizon Therapeutics Plc | $2,087.53 | 2019-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $1,820.91 | 2019-2025 | |
| Janssen Biotech, INC. | $1,684.95 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Ucb, INC. | $1,380.78 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $1,010.51 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $809.02 | 2019-2025 | Orencia |
| Glaxosmithkline, LLC. | $739.87 | 2019-2025 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $739.46 | 2019-2025 | Ofev, Cyltezo, Spevigo |
| Lilly USA, LLC | $712.48 | 2019-2023 | Taltz |
| Ani Pharmaceuticals, INC. | $530.57 | 2022-2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $486.70 | 2020-2025 | Acthar |
| Astrazeneca Pharmaceuticals LP | $449.59 | 2021-2025 | Saphnelo |
| Radius Health, INC. | $347.19 | 2020-2025 | Tymlos |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $267.17 | 2019-2024 | |
| Aurinia Pharma U.S., INC. | $239.67 | 2021-2025 | Lupkynis |
| Sandoz INC. | $148.02 | 2023-2024 | Hyrimoz |
| Mallinckrodt Enterprises LLC | $135.66 | 2019 | |
| Organon LLC | $129.19 | 2023-2025 | Renflexis, Hadlima |
| Genentech USA, INC. | $89.16 | 2019-2025 | Gazyva |
| Alexion Pharmaceuticals, INC. | $80.66 | 2019-2024 | Strensiq |
| Invivyd INC | $72.42 | 2025 | Pemgarda |
| Antares Pharma, INC. | $47.46 | 2019 | |
| Fresenius Kabi USA, LLC | $38.58 | 2024-2025 | Idacio |
| Celgene Corporation | $38.03 | 2019 | |
| Octapharma USA, INC. | $37.63 | 2025 | Octagam Immune Globulin (Human) |
| Actelion Pharmaceuticals US, INC. | $32.54 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $30.50 | 2019-2021 | |
| Eisai INC. | $30.44 | 2025 | |
| Janssen Scientific Affairs, LLC | $26.12 | 2019-2020 | |
| Boston Scientific Corporation | $24.20 | 2021 | |
| Fidia Pharma USA INC. | $21.69 | 2019 | |
| Sobi, INC | $19.25 | 2024 | |
| Hikma Pharmaceuticals USA | $14.75 | 2020 | |
| Oxford Immunotec USA INC | $12.77 | 2022 | |
| Medexus Pharma, INC. | $11.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madhurika Samakur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.